We accept them, but with misgivings.  Would like to get a sense of the
answers to get some feel of general practice and a better sense of issues
involved.

-----Original Message-----
From: Sullivan, Diane [mailto:xxxxxx@NJC.ORG]
Sent: Friday, August 29, 2003 4:51 PM
To: xxxxxx@HRINET.ORG
Subject: [RESADM-L] Clinical Trial Enrollment Incentives

We are interested in finding out what types of policies other institutions
have governing the acceptance of clinical trial enrollment incentives.  Do
you accept them if they are tied to the increased costs of rapid enrollment,
decline them if they are simply bonus payments, take them either way,
decline them either way?  If any of you have policies that you are willing
to share we would certainly appreciate it.

You may reply to the list or to me at xxxxxx@njc.org.

Thank you for your thoughts.

Diane Sullivan
National Jewish Medical and Research Center
CONFIDENTIALITY NOTICE: The information contained in this message is legally
privileged and confidential information intended for the use of the
individual or entity named above. If the reader of this message is not the
intended recipient, or the employee or agent responsible to deliver it to
the intended recipient, you are hereby notified that any release,
dissemination, distribution, or copying of this communication is strictly
prohibited. If you have received this communication in error, please notify
the author immediately by replying to this message and delete the original
message. Thank you.

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================

This e-mail and any files transmitted with it may contain information that
is PRIVILEGED, CONFIDENTIAL, and exempt from disclosure under applicable
law.  It is intended only for the individual(s) or entity named above.  If
you are not an intended recipient of this e-mail, you are hereby notified
that any unauthorized use, dissemination or copying of this e-mail or the
information contained in it or attached to it is strictly prohibited.  If
you have received this e-mail in error, please delete it and immediately
notify the person named above by reply e-mail.  Thank you.

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================